Aktis Financial Statements From 2010 to 2026

Stocks . USA . 
Stock . Aktis Oncology Common
AKTS Stock  USD 20.25  0.61  3.11%   
Aktis Oncology's financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing Aktis Oncology's valuation are provided below:
Gross Profit
-58 M
Market Capitalization
1.1 B
Enterprise Value Revenue
159.5311
Revenue
5.6 M
Earnings Share
(1.16)
There are over ninety-five available fundamental signals for Aktis Oncology Common, which can be analyzed over time and compared to other ratios. All traders should validate Aktis Oncology's prevailing fundamentals against the performance from 2010 to 2026 and make sure the trends continue to evolve in the right direction.

Aktis Oncology Total Revenue

1.62 Million

Check Aktis Oncology financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Aktis Oncology's main balance sheet or income statement drivers, such as Depreciation And Amortization of 2 M, Selling General Administrative of 9.1 M or Other Operating Expenses of 31.4 M, as well as many indicators such as Price To Sales Ratio of 0.0, Dividend Yield of 0.0 or PTB Ratio of 0.0. Aktis financial statements analysis is a perfect complement when working with Aktis Oncology Valuation or Volatility modules.
  
Build AI portfolio with Aktis Stock
Check out the analysis of Aktis Oncology Correlation against competitors.

Aktis Oncology Balance Sheet

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Total Assets393.9 M375.1 M100.7 M
Slightly volatile
Short and Long Term Debt Total15.4 M13.8 M11.2 M
Slightly volatile
Total Current Liabilities22.7 M21.6 M6 M
Slightly volatile
Cash38.3 M42.7 M27.9 M
Slightly volatile
Cash And Short Term Investments358.8 M341.7 M83.6 M
Slightly volatile
Liabilities And Stockholders Equity393.9 M375.1 M100.7 M
Slightly volatile
Non Current Liabilities Total477.2 M454.4 M102.8 M
Slightly volatile
Total Liabilities499.9 M476.1 M108.8 M
Slightly volatile
Total Current Assets363.3 M346 M85.7 M
Slightly volatile
Short Term Debt1.6 M1.5 M577.6 K
Slightly volatile
Common Stock148.5 K141.4 K47.4 K
Slightly volatile
Other Current Liabilities7.6 M7.3 M2.9 M
Slightly volatile
Property Plant And Equipment Net17.5 M24 M12.3 M
Slightly volatile
Accounts Payable1.1 M2.2 M823.3 K
Slightly volatile
Non Current Assets Total20.5 M29.1 M14.4 M
Slightly volatile
Non Currrent Assets Other5.4 M5.1 M1.1 M
Slightly volatile
Common Stock Shares Outstanding107.6 M102.4 M39.6 M
Slightly volatile
Inventory1.8 M2.6 M1.6 M
Slightly volatile
Other Current Assets4.4 M4.2 M1.5 M
Slightly volatile
Other Stockholder Equity5.4 M5.6 M42.3 M
Pretty Stable
Intangible Assets15.2 M14.4 M4.9 M
Slightly volatile
Net Receivables6.4 M6.1 M2 M
Slightly volatile
Good Will7.8 M5.9 M8.6 M
Pretty Stable
Capital Lease Obligations10 M13.8 M4.3 M
Slightly volatile
Property Plant And Equipment Gross19.1 M27.7 M9.6 M
Slightly volatile
Non Current Liabilities Other4.8 K5.4 K5.9 K
Slightly volatile
Net Working Capital184.5 M324.3 M149.3 M
Slightly volatile

Aktis Oncology Income Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Depreciation And Amortization2 M1.8 M1.3 M
Slightly volatile
Selling General Administrative9.1 M13 M6.8 M
Slightly volatile
Other Operating Expenses31.4 M61.6 M23.1 M
Slightly volatile
Research Development49.5 M47.1 M16.4 M
Slightly volatile
Total Operating Expenses64.6 M61.6 M23.7 M
Slightly volatile
Cost Of Revenue33.9 M32.3 M10.5 M
Slightly volatile
Interest Expense2.4 M3.1 M1.4 M
Slightly volatile
Net Interest Income5.5 M9.3 M2.9 M
Slightly volatile
Interest Income5.5 M9.3 M2.9 M
Slightly volatile
Reconciled Depreciation1.2 M1.8 M673.1 K
Slightly volatile

Aktis Oncology Cash Flow Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Stock Based Compensation4.3 M2.6 M3 M
Slightly volatile
Begin Period Cash Flow37.4 M35.3 M24.7 M
Slightly volatile
Depreciation2 M1.8 M1.3 M
Slightly volatile
Capital Expenditures3.1 M3.3 M4.1 M
Slightly volatile
Total Cash From Financing Activities221.3 M210.8 M59.3 M
Slightly volatile
End Period Cash Flow42.5 M44.1 M29.4 M
Slightly volatile

Financial Ratios

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Stock Based Compensation To Revenue1.221.371.4934
Slightly volatile
Capex To Depreciation3.82.094.6155
Slightly volatile
Sales General And Administrative To Revenue6.086.847.4693
Slightly volatile
Research And Ddevelopement To Revenue22.0324.7927.0553
Slightly volatile
Capex To Revenue1.541.731.8906
Slightly volatile
ROE0.750.580.8571
Slightly volatile
Net Debt To EBITDA0.540.575.1428
Slightly volatile
Current Ratio20.9718.3823.4055
Slightly volatile
Debt To Assets0.04250.03310.0229
Slightly volatile
Enterprise Value Over EBITDA0.540.575.1428
Slightly volatile
Ebt Per Ebit0.950.970.9048
Very volatile
Quick Ratio20.9718.3823.4055
Slightly volatile
Cash Ratio2.162.2719.2975
Slightly volatile
Operating Cash Flow Sales Ratio7.948.939.7518
Slightly volatile
Free Cash Flow Operating Cash Flow Ratio1.120.931.0962
Slightly volatile
Fixed Asset Turnover0.0570.06410.07
Slightly volatile
Enterprise Value Multiple0.540.575.1428
Slightly volatile
Debt Ratio0.04250.03310.0229
Slightly volatile
Asset Turnover0.00360.00410.0045
Slightly volatile
Return On Equity0.750.580.8571
Slightly volatile

Aktis Fundamental Market Drivers

Aktis Upcoming Events

6th of February 2024
Upcoming Quarterly Report
View
13th of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
4th of September 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
30th of June 2023
Last Financial Announcement
View

About Aktis Oncology Financial Statements

Aktis Oncology shareholders use historical fundamental indicators, such as revenue or net income, to determine how well the company is positioned to perform in the future. Although Aktis Oncology investors may analyze each financial statement separately, they are all interrelated. The changes in Aktis Oncology's assets and liabilities, for example, are also reflected in the revenues and expenses on on Aktis Oncology's income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.
Last ReportedProjected for Next Year
Current Deferred Revenue10.7 M11.2 M
Total Revenue1.7 M1.6 M
Cost Of Revenue32.3 M33.9 M
Stock Based Compensation To Revenue 1.37  1.22 
Sales General And Administrative To Revenue 6.84  6.08 
Research And Ddevelopement To Revenue 24.79  22.03 
Capex To Revenue 1.73  1.54 
Ebit Per Revenue(31.50)(33.08)

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.
Explore Investing Ideas  

Additional Tools for Aktis Stock Analysis

When running Aktis Oncology's price analysis, check to measure Aktis Oncology's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Aktis Oncology is operating at the current time. Most of Aktis Oncology's value examination focuses on studying past and present price action to predict the probability of Aktis Oncology's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Aktis Oncology's price. Additionally, you may evaluate how the addition of Aktis Oncology to your portfolios can decrease your overall portfolio volatility.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2026 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY